News

Answer ALS: A Revolutionary Project to Cure ALS

The launch of Answer ALS, the largest comprehensive research project to cure Amyotrophic Lateral Sclerosis (ALS) was announced in a press release by the Johns Hopkins University’s Robert Packard Center for ALS Research in Baltimore, MD, the Cedars-Sinai…

MediciNova Enrolls First Advanced ALS Patient On Non-Invasive Ventilation In Ibudilast Trial

MediciNova, a biopharmaceutical company that creates and studies small molecule medications for the management of medical conditions with unmet medical needs, is currently undergoing research on ALS patients who use non-invasive ventilation and will be treated with MN-166, also called Ibudilast, as part of a study on the management of ALS. Currently there…

Karyopharm Therapeutics Announces Advance of Neuroprotective SINE(TM) Compounds for Amyotrophic Lateral Sclerosis

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs for the treatment of cancer and other major diseases, recently announced the evaluation of its SINE nuclear transport compound KPT-350 as a treatment for Amyotrophic Lateral Sclerosis (ALS). Results from preclinical studies will…

Device That Aids Breathing in ALS Patients May Decrease Survival

A recent study indicates that a respiratory pacemaker intended to assist breathing in people with amyotrophic lateral sclerosis (ALS) may actually reduce survival in those with the neurodegenerative disorder. The study, titled “Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis…

Synapse Biomedical To Present Data on NeuRx Diaphragm Pacing System In ALS Patients

Synapse Biomedical Inc., a company that commercializes the NeuRx Diaphragm Pacing System (DPS), has recently announced it will be presenting data on the company’s Post Approval Study (PAS), a multi-center trial that demonstrated DPS’s safety and survival benefit, during the 26th International Symposium on ALS/MND. Data will be presented by Dr. Robert Miller, Principal Investigator of the…

Two New Studies Identify Disrupted Trafficking Inside Neurons as the Cause for Known ALS Mutation

Two new studies, one entitled “GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport” and another “The C9orf72 repeat expansion disrupts nucleocytoplasmic transport”, report the discovery of a key mechanism underlying amyotrophic lateral sclerosis’ onset which is associated with C9orf72 mutation (the most common genetic defect…

New ALS Research Project Financed by Ice Bucket Challenge

Last year the Ice Bucket Challenge made headlines across America when the Barrow Neurological Institute raised more than $500,000 through the international fundraising and advocacy initiative. Now, the organization is reporting that the funds accumulated will be used to support a new and potentially groundbreaking amyotrophic lateral sclerosis (ALS) study to determine why…